

FUND FACTSHEET

EDENTREE RESPONSIBLE AND SUSTAINABLE UK EQUITY FUND

SHARE CLASS A

July 2021



Investment Objective

To achieve long-term capital appreciation over five years or more and an income, through a diversified portfolio of UK companies. The EdenTree Responsible and Sustainable UK Equity Fund aims to invest at least 80% in UK companies whose primary listing is in the UK by investing in a portfolio of companies which make a positive contribution to society and the environment through sustainable and socially responsible practices.

Fund Manager

Manager Name:	Sue Round
Start Date:	01/03/1988
Manager Name:	Ketan Patel
Start Date:	01/09/2016

Price Information

Single price:	264.60p (as at 31/07/2021)
Currency:	GBP
Pricing:	Daily
Historic Yield*:	0.38%

Fund Facts

Fund Size:	£176.79m
IA Sector:	IA UK All Companies
Index**:	FTSE All Share
Asset Class:	Equity
Launch Date:	01/03/1988
Domicile:	United Kingdom
ISA:	Available and Eligible
Number of Holdings:	56
Minimum Investment:	£1,000

Identifiers

Sedol:	0937131
ISIN:	GB0009371310

Dividends

Ex-Dividend Date:	01/01, 01/07
Dividend Pay Date:	30/04, 31/08

Charges

AMC:	1.25%
Ongoing Charge:	1.34%
Initial Charge:	0.00%

Fund Manager Commentary

July saw the FTSE 100, FTSE 250 and FTSE small cap return 0.6%, 3.0% and 0.1% respectively. The prime minister announced a move to step four of the government's coronavirus easing plan which saw the end of the work from home guidance, enforced wearing of face coverings and social distancing rules. In terms of portfolio activity we took part in the IPO of Microlise, a leading provider of transport management software to fleet operators helping them to improve efficiency, safety, and reduce emissions. We added to the positions in Spectris, Johnson Services, Keller Group, National Express, Close Brothers, Taylor Wimpey, Smith & Nephew, Prudential, Bioventix, WH Smith, IP Group, Sabre Insurance, James Fisher & Sons, Clinigen, Mattioli Woods and Hotel Chocolat. We participated in a capital raise by Hotel Chocolat, with the funding being used to increase long term sales capacity. Fund outperformance was due to being overweight in Pharmaceuticals & Biotechnology, Electronic & Electrical Equipment and Construction Materials. At a stock level, the positions in Dechra Pharmaceuticals, Genus and Halma aided performance, whilst Sabre Insurance and Smith & Nephew were a drag. The Fund's performance remains ahead of benchmark across all meaningful periods and continues to take material inflows.

Cumulative Performance (as at 31/07/2021)



Cumulative Performance (as at 31/07/2021)

	1m	3m	6m	1y	3y	5y	10y
Fund	2.20%	2.28%	11.25%	26.94%	11.05%	32.44%	105.28%
IA Sector	1.30%	2.64%	14.13%	32.00%	11.56%	41.22%	108.03%

Discrete Annual Performance (as at 31/12/2020)

	2016	2017	2018	2019	2020
Fund	3.60%	11.88%	-12.89%	25.60%	-6.30%
IA Sector	10.95%	14.05%	-11.15%	22.37%	-6.17%

Fund and Sector performance reported in GBP base currency, calculated on a net total return NAV to NAV basis with income reinvested into the Fund.

Source: © 2021 Morningstar. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and its content providers; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; (5) are not warranted to be complete, accurate or timely; and (6) may be drawn from data published on various dates. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use.

Top 10 Holdings

Name	
DECHRA PHARMA	5.04%
HALMA PLC	4.66%
GENUS PLC	3.60%
ASTRAZENECA PLC	3.25%
OXFORD INSTR	3.20%
SMITH & NEPHEW	2.98%
RELX PLC	2.98%
SPECTRIS PLC	2.81%
PRUDENTIAL PLC	2.70%
VICTREX PLC	2.68%

Ratings and Awards

FE fundinfo Crown Rating



Rayner Spencer Mills Rating



Contact Information

EdenTree Investment Management
Sunderland
SR43 4AU

Financial Advisers – 0800 032 1893
Wealth & Discretionary – 0800 011 3821
Private individuals – 0800 358 3010
Charities – 0800 032 3778


www.edentreeim.com

From 1 January 2021 the EdenTree Amity UK Fund became the EdenTree Responsible and Sustainable UK Equity Fund.

Past performance should not be seen as a guide to future performance. The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations, you may not get back the amount originally invested. This factsheet should not be interpreted as financial advice. If you are unsure which investment is most suited for you, the advice of a qualified financial adviser should be sought.

EdenTree Investment Management Limited (EdenTree) Reg. No. 2519319. Registered in England at Benefact House, 2000, Pioneer Avenue, Gloucester Business Park, Brockworth, Gloucester, GL3 4AW, United Kingdom. EdenTree is authorised and regulated by the Financial Conduct Authority and is a member of the Investment Association. Firm Reference Number 527473.

Capitalisation of Equity Assets



Sector Breakdown

Industrials	34.00%
Health Care	19.95%
Financials	19.37%
Consumer Disc.	15.24%
Technology	4.74%
Basic Materials	4.30%
Consumer Staples	1.90%
Real Estate	0.44%
Cash	0.06%



Region Breakdown

United Kingdom	99.42%
United States	0.52%
Cash	0.06%



Asset Breakdown

UK Equities	99.42%
Overseas Equities	0.52%
Cash	0.06%



Yield figures are as at 31/07/2021. Rounding may cause small differences in percentages included in this document.

*Past 12 months' distributions as a % of midshare price, excluding preliminary charge.

**We compare the fund's performance to the FTSE All Share Index, however the portfolio manager is not bound or influenced by the index when making investment decisions.